Sudo Biosciences Appoints Paul Bavier As Chief Legal Counsel
04 Dec 2025 //
BUSINESSWIRE
Sudo Biosciences Reports Successful Phase 1 Trial for SUDO-550
28 Oct 2025 //
BUSINESSWIRE
Sudo Biosciences Doses First Participants in TYK2 Inhibitor Trial
02 Dec 2024 //
BUSINESSWIRE
Sudo Biosciences Announces Second Close of Upsized Series B Financing
13 Feb 2024 //
BUSINESSWIRE

Market Place
Sourcing Support